
|Videos|June 15, 2017
Safety Results for Daratumumab Combined With Carfilzomib, Lenalidomide, and Dexamethasone in Multiple Myeloma
Author(s)Andrzej Jakubowiak, MD, PhD
Andrzej Jakubowiak, MD, PhD, professor of Medicine, University of Chicago Medicine, discusses safety results from an open label, phase 1b trial exploring daratumumab (Darzalex) combined with carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone in patients with newly diagnosed multiple myeloma.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Rethinking Advanced Prostate Cancer: Surprising Finds from a Landmark Study
2
Long-Term Follow-Up Confirms Benefits of Low-Dose Seminoma Treatment
3
FDA Accepts NDA for 177Lu-edotreotide in GEP-NETs
4
How Resting Immune Cells Could Be the Key to Fighting Prostate Cancer
5









































